Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Convertible Debt: 2020-2024

Historic Convertible Debt for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to $738.9 million.

  • BridgeBio Pharma's Convertible Debt rose 0.27% to $739.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $739.9 million, marking a year-over-year increase of 0.27%. This contributed to the annual value of $738.9 million for FY2024, which is 0.27% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Convertible Debt of $738.9 million as of FY2024, which was up 0.27% from $736.9 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Convertible Debt high stood at $738.9 million for FY2024, and its period low was $383.4 million during FY2020.
  • In the last 3 years, BridgeBio Pharma's Convertible Debt had a median value of $736.9 million in 2023 and averaged $736.9 million.
  • Data for BridgeBio Pharma's Convertible Debt shows a peak YoY soared of 91.20% (in 2021) over the last 5 years.
  • BridgeBio Pharma's Convertible Debt (Yearly) stood at $383.4 million in 2020, then spiked by 91.20% to $733.1 million in 2021, then climbed by 0.25% to $735.0 million in 2022, then grew by 0.26% to $736.9 million in 2023, then climbed by 0.27% to $738.9 million in 2024.